Browse drugs

…dupilumab n=573; placebo n=562) had baseline BEC ≥300 cells/µL. Dupilumab reduced annualized exacerbation rates vs placebo by 36.9% (BEC …

…nts (BECs) in COPD are associated with an increased response to inhaled corticosteroid (ICS). Post-hoc analyses of randomised clinical trials of ICS-c…

…s highlighted by the LifeArc Translational Challenge programme. Glatiramer acetate (GA), currently used to treat multiple sclerosis, is similar in…

…in the SWIFT-1/2 studies, 260 received placebo and 502 received depemokimab. Depemokimab was associated with reduced exacerbation rates ver…

…7 (0.3); AER 3.9 (0.5).The mean changes (95% CI) in response to tezepelumab were as follows: total IgE 207.3 kU/L (49.9, 364.7) p<0.05, eos…

…r refractory HRF patients with good NIV compliance who received acetazolamide. No evidence of harm demonstrated. If instituted sooner, it mig…

…th mPAP ≤30 mmHg and ≤25 mmHg conferring the best prognosis for BPA and PEA-treated patients, respectively. These data should encou…

…significant implications for clinical practice, suggesting that butylphthalide could be incorporated into standard post-stroke care regimens t…

…e and renal impairment complications, particularly for the drug tenecteplase. Therefore, we examined the association of impaired renal funct…

…n, decreased pancreatic β-cell function and the combined use of metformin may also contribute to the risk of DKA in patients treated with…

…ted in ChatGPT 4.0 outputs at a 10th-grade reading level, while Gemini 1.0 Pro outputs were at a 7th-grade level. Both LLMs produced outputs a…

…tier Hospital pharmacy has chosen to establish a shelf life for clozapine tablets of 84 days.…